Skip to main content

Advertisement

Table 2 Association of anti-PD1 with clinical features of new-onset SLE patients

From: Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients

Clinical manifestations p value Odds ratio 95% CI
Malar rash 0.001 15.773 3.065–81.186
Discoid rash 0.077 12.688 0.762–211.274
Arthritis <0.001 22.937 4.619–113.9
Oral ulcer 0.279 3.830 0.336–43.256
Photosensitivity 0.477 4.042 0.086–189.971
Vasculitis 0.216 4.851 0.398–59.109
Raynaud’s phenomenon 0.657 2.266 0.061–84.212
Serositis 0.007 16.008 2.119–120.967
Hematological involvement <0.001 35.187 6.459–191.679
Renal involvement 0.024 8.306 1.323–52.132
Neurological involvement 0.027 37.282 1.497–928.697
  1. PD-1 programmed cell death protein 1, SLE systemic lupus erythematosus